Skip to main content

Table 2 Demographic characteristics and diagnosis of users of the originator etanercept, by cohort

From: Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia

 

Cohort

 

Historical

Policy

Demographic

2016 (n = 1878)

2017 (n = 1963)

2018 (n = 1823)

2019 (n = 1694)

 Age median (range), years

59.0 (3.0–94.0)

59.0 (3.0–95.0)

60.0 (3.0–96.0)

61.0 (3.0–97.0)

 Female

1181 (62.9)

1232 (62.8)

1126 (61.8)

1017 (60.0)

Diagnosisa

 Rheumatoid arthritis

1185 (63.1)

1230 (62.7)

1087 (59.6)

996 (58.8)

 Juvenile rheumatoid arthritis

49 (2.6)

63 (3.2)

62 (3.4)

48 (2.8)

 Ankylosing spondylitis

188 (10.0)

201 (10.2)

201 (11.0)

181 (10.7)

 Psoriatic arthritis

237 (12.6)

265 (13.5)

286 (15.7)

300 (17.7)

 Undetermined

219 (11.7)

204 (10.4)

187 (10.3)

169 (10.0)

 More than one diagnosis

142 (7.6)

142 (7.2)

130 (7.1)

118 (7.0)

  1. Numbers represent patients (% of cohort) unless otherwise specified
  2. aIdentified based on at least five visits to a physician or emergency department, or at least one discharge from hospital with a diagnosis code for one of the four conditions in the five years before cohort entry. Rheumatoid arthritis: International Classification of Diseases (ICD)-9 code 714 (except 714.3, 714.4); ICD-10 codes M05, M06 (age at first diagnosis > 18 years). Juvenile rheumatoid arthritis: ICD-9 codes 714, 714.3; ICD-10 codes M05, M06, M08 (age at first diagnosis ≤ 18 years). Ankylosing spondylitis: ICD-9 code 720 (except 720.1–720.9); ICD-10 code M45. Psoriatic arthritis: ICD-9 code 696.0; ICD-10 code M07
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us